Emerald Advisers Inc. PA Sells 93,487 Shares of Catalent Inc (CTLT)

Share on StockTwits

Emerald Advisers Inc. PA decreased its holdings in shares of Catalent Inc (NYSE:CTLT) by 17.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 441,501 shares of the company’s stock after selling 93,487 shares during the quarter. Emerald Advisers Inc. PA owned approximately 0.30% of Catalent worth $20,110,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CTLT. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Catalent in the second quarter valued at $1,508,000. Millennium Management LLC lifted its stake in Catalent by 4,244.2% in the second quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock valued at $50,279,000 after acquiring an additional 1,172,638 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in Catalent in the second quarter valued at $6,653,000. Massachusetts Financial Services Co. MA lifted its stake in Catalent by 15.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 15,152 shares of the company’s stock valued at $635,000 after acquiring an additional 2,075 shares during the last quarter. Finally, CWM LLC lifted its stake in Catalent by 119.4% in the second quarter. CWM LLC now owns 186,266 shares of the company’s stock valued at $7,803,000 after acquiring an additional 101,374 shares during the last quarter. Institutional investors and hedge funds own 91.80% of the company’s stock.

In other news, SVP Lance Miyamoto sold 6,525 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John R. Chiminski sold 130,545 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $45.32, for a total transaction of $5,916,299.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 184,335 shares of company stock valued at $8,161,727. 1.40% of the stock is currently owned by corporate insiders.

CTLT has been the subject of a number of recent analyst reports. UBS Group initiated coverage on shares of Catalent in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target for the company. JPMorgan Chase & Co. increased their price target on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Finally, Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $49.33.

NYSE CTLT opened at $40.34 on Thursday. The company has a quick ratio of 1.79, a current ratio of 2.15 and a debt-to-equity ratio of 2.44. The stock has a market cap of $5.61 billion, a PE ratio of 25.37, a P/E/G ratio of 2.30 and a beta of 1.41. Catalent Inc has a 52-week low of $36.73 and a 52-week high of $47.87.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.06. The company had revenue of $685.30 million during the quarter, compared to analysts’ expectations of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. Catalent’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.65 EPS. As a group, equities research analysts expect that Catalent Inc will post 1.72 earnings per share for the current year.

Catalent Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also: Investing strategies using the yield curve

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply